Zoledronic Acid — Membership Pricing

Other medications in Bone Health

• Abaloparatide
• Calcitonin
• Calcium Carbonate
• Denosumab
• Etidronate
• Romosozumab
• Teriparatide

About Zoledronic Acid

Zoledronic acid is a vital medication used to strengthen bones and manage various bone-related conditions, often administered via infusion. Understanding its benefits and costs is crucial for patients. ### What Zoledronic Acid Treats

Zoledronic acid is a potent bisphosphonate medication primarily prescribed to improve bone health and manage conditions that affect bone density and strength. It's commonly used to treat osteoporosis, a condition that causes bones to become weak and brittle, particularly in postmenopausal women and men, as well as osteoporosis induced by glucocorticoid medications. It also plays a crucial role in managing Paget's disease of bone, where bone remodeling is abnormal. Furthermore, zoledronic acid is instrumental in treating hypercalcemia of malignancy (high blood calcium levels due to cancer) and reducing skeletal-related events, such as fractures, in patients with multiple myeloma and bone metastases from solid tumors. ### How It Works

As a bisphosphonate, zoledronic acid works by slowing down the activity of osteoclasts, which are the cells responsible for breaking down bone tissue. By inhibiting these cells, the medication helps to prevent bone loss, allowing osteoblasts (bone-building cells) to work more effectively. This process ultimately leads to increased bone density and strength, reducing the risk of fractures and mitigating the progression of bone diseases. Zoledronic acid is typically administered as an intravenous (IV) infusion, meaning it's delivered directly into a vein, usually once a year for osteoporosis or more frequently for cancer-related bone conditions, depending on the specific diagnosis and doctor's orders. ### Typical Costs of Zoledronic Acid

Without insurance, the cost of zoledronic acid can be substantial. A single infusion can range from several hundred to well over a thousand dollars, depending on the dosage, the healthcare facility administering it, and your geographic location. These costs can be a significant barrier for many individuals needing this crucial treatment, even with insurance, as

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Zoledronic Acid is approved for (FDA label)

Zoledronic Acid Injection is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) Treatment to increase bone mass in men with osteoporosis ( 1.3 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) Treatment of Paget's disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women Zoledronic Acid Injection is indicated for treatment of osteoporosis in postmenopausal women.

Source: Read the full FDA label on DailyMed. Label effective date: July 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Zoledronic Acid (FDA label)

5 mg in a 100 mL ready to infuse solution. 5 mg in a 100 mL ready-to-infuse solution ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8aac81ae-f92c-4f0b-b480-44badf72b5f5. SPL document ID: d5f493cd-f7fb-46e1-9b6d-22430c987061. Label effective date: July 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Zoledronic Acid (FDA label)

The following clinically significant adverse drug reactions are described elsewhere in the labeling: • Drugs with Same Active Ingredient [see Warnings and Precautions ( 5.1 )] • Hypocalcemia and Mineral Metabolism [see Warnings and Precautions ( 5.2 )] • Renal Impairment [see Warnings and Precautions ( 5.3 )] • Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.4 )] • Atypical Fractures Including Femoral Fractures [see Warnings and Precautions ( 5.5 )] • Musculoskeletal Pain [see Warnings and Precautions ( 5.6 )] • Patients with Asthma [see Warnings and Precautions ( 5.7 )] The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 8aac81ae-f92c-4f0b-b480-44badf72b5f5. SPL document ID: d5f493cd-f7fb-46e1-9b6d-22430c987061. Label effective date: July 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Zoledronic Acid (FDA label)

Zoledronic acid injection is contraindicated in patients with the following conditions: Hypocalcemia [see Warnings and Precautions ( 5.2 )] Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions ( 5.3 )] . Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions ( 6.2 )] . Hypocalcemia ( 4 ) Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: 8aac81ae-f92c-4f0b-b480-44badf72b5f5. SPL document ID: d5f493cd-f7fb-46e1-9b6d-22430c987061. Label effective date: July 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Zoledronic Acid (FDA label)

Products Containing Same Active Ingredient : Patients receiving Zometa ® should not receive zoledronic acid injection ( 5.1 ) Hypocalcemia may worsen during treatment. Patients must be adequately supplemented with calcium and vitamin D ( 5.2 ) Renal Impairment : A single dose should not exceed 5 mg and the duration of infusion should be no less than 15 minutes. Renal toxicity may be greater in patients with underlying renal impairment or with other risk factors, including advanced age or dehydration. Monitor creatinine clearance before each dose ( 2.7 , 5.3 ) Osteonecrosis of the Jaw (ONJ) has been reported. All patients should have a routine oral exam by the prescriber prior to treatment ( 5.4 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture.

Source: FDA prescribing information (DailyMed). Set ID: 8aac81ae-f92c-4f0b-b480-44badf72b5f5. SPL document ID: d5f493cd-f7fb-46e1-9b6d-22430c987061. Label effective date: July 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Zoledronic Acid (FDA label)

No in vivo drug interaction studies have been performed for zoledronic acid injection. In vitro and ex vivo studies showed low affinity of zoledronic acid for the cellular components of human blood. In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL. In vivo studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug. Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) Loop Diuretics: May increase risk of hypocalcemia ( 7.2 ) Nephrotoxic Drugs: Use with caution ( 7.3 ) Drugs Primarily Excreted by the Kidney: Exposure may be increased with renal impairment.

Source: FDA prescribing information (DailyMed). Set ID: 8aac81ae-f92c-4f0b-b480-44badf72b5f5. SPL document ID: d5f493cd-f7fb-46e1-9b6d-22430c987061. Label effective date: July 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.